OncoMatch/Clinical Trials/NCT07030712
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Is NCT07030712 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for metastatic neoplasm.
Treatment: MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 · MK-8294 — MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Prior therapy
Must have received: standard treatment
have previously failed standard treatment, lack standard treatment options, or are intolerant to standard treatment
Cannot have received: immunotherapy
Exception: except endocrine disorders that can be treated with replacement therapy
Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwestern University ( Site 0101) · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify